As expected, the higher expression of Bcl‐xL in solid tumors led to a clinical investigation of a dual Bcl‐xL/Bcl‐2 inhibitor (ABT‐263, also called navitoclax), which exhibited frequent dose‐dependent thrombocytopenia. The gene discussed is BCL2L1; the disease is Thrombocytopenia.